



August 26-27, 2024

**Advisory Panel on Hospital Outpatient Payment Presentation:
Separate Payment for Diagnostic Radiopharmaceuticals**

As representatives of the Council on Radionuclides and Radiopharmaceuticals (CORAR) and the Medical Imaging & Technology Alliance (MITA), we are writing to thank the members of the Hospital Outpatient Payment (HOP) Panel for your previous support of separate payment for diagnostic radiopharmaceutical drugs under the Hospital Outpatient Prospective Payment System (OPPS). Our organizations want to relay a strong consensus of support for CMS' proposal in the Calendar Year (CY) 2025 OPPS Proposed Rule to implement separate payment for diagnostic radiopharmaceutical drugs above a certain threshold.

CORAR and MITA represent the major manufacturers and distributors of diagnostic radiopharmaceutical drugs. Together, we have advocated for establishing separate payment for diagnostic radiopharmaceutical drugs because packaged payment has presented a significant barrier to patient access to these products in the outpatient setting, limiting Medicare patients' ability to benefit from the role that advanced diagnostic radiopharmaceutical drugs play in guiding the treatment of serious diseases such as cancer and Alzheimer's disease.

CMS' proposal to provide separate payment for diagnostic radiopharmaceuticals above a certain cost threshold starting in CY 2025 would meaningfully support Medicare beneficiaries' access to innovative diagnostic radiopharmaceuticals and we respectfully request the HOP Panel recommend that CMS finalize its proposal to pay separately for diagnostic radiopharmaceuticals at a set threshold.

Sincerely,

Council on Radionuclides and Radiopharmaceuticals (CORAR)
Medical Imaging & Technology Alliance (MITA)